Large population-based study suggests no increased major malformation risk following maternal first trimester atomoxetine use
A collaborative of researchers from Nordic countries and the US have published a population-based comparative cohort study including approximately 2.4 million pregnancies ending in live births in Denmark, Iceland, Norway, and Sweden (2003-2017) and approximately 1.8 million in the US, investigating the risk of major malformation following maternal first trimester atomoxetine use. More information can be found here.
Photo by Milad Fakurian on Unsplash